Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05985915 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
A Phase 3 study of Sjogren's Syndrome, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 612
- Enrollment target
- 20
- Study locations
NCT05985915 is a Phase 3 study of Sjogren's Syndrome that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 612 participants, above the 258-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (137% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT05985915, a Phase 3 study of Sjogren's Syndrome, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 612 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 \[NCT05350072\] or CVAY736A2302 \[NCT05349214\]).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ianalumab (VAY736)
Study Locations (20)
Florida
- Bay Area Arthritis And Osteoporosis - Brandon
- GNP Research - Cooper City
- Sarasota Arthritis Res Ctr - Sarasota
- West Broward Rheumatology Associates Inc - Tamarac
California
- Providence Medical Foundation - Fullerton
- Advanced Medical Research - La Palma
- Medvin Clinical Research - Van Nuys
North Carolina
- On Site Clinical Solutions Llc - Charlotte
- Arthritis and Osteoporosis - Charlotte
- Carolina Arthritis Associates - Wilmington
Georgia
- Augusta University Georgia - Augusta
- North GA Rheumatology Group PC - Suwanee
New York
- Winthrop University Hospital - Mineola
- St Lawrence Health System - Potsdam
Illinois
- Clin Invest Specialists Inc - Orland Park
Kansas
- University of Kansas Hospital - Kansas City
Louisiana
- Ochsner Health System - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2023-10-27 |
| Est. Completion | 2033-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05985915
The ClinicalTrials.gov registry entry for NCT05985915 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 612 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 258-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (137% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sjogren's Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05985915 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05985915 about?
NCT05985915 is a clinical study titled "A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.". The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 \[NCT05350072\] or CVAY736A2302 \[NCT05349214\]).
What is the current status of trial NCT05985915?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 612 participants. The study started on 2023-10-27. Estimated completion is 2033-04-22.
What conditions does trial NCT05985915 study?
This clinical trial studies the following conditions: Sjogren's Syndrome.
What interventions are being tested in trial NCT05985915?
The interventions under investigation include: Placebo (OTHER), Ianalumab (VAY736) (DRUG).
Who is sponsoring clinical trial NCT05985915?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05985915 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
ACTIVE NOT RECRUITING · Phase 3
-
Nipocalimab in Moderate to Severe Sjogren's Disease
ACTIVE NOT RECRUITING · Phase 3
-
Rheumatology Diet Study
RECRUITING
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
RECRUITING · Phase 1
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.